Rosińska Magdalena, Dubiański Roman, Konieczna Aleksandra, Poleszczuk Jan, Pawlik Hubert, Nowecki Zbigniew I, Kamiński Eryk
Computational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Breast Cancer and Reconstructive Surgery Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Cancers (Basel). 2024 Mar 7;16(6):1087. doi: 10.3390/cancers16061087.
Triple-negative breast cancer (TNBC) poses a serious therapeutic challenge due to the occurrence of frequently aggressive, heterogenic, and metastatic tumours. The absence of therapeutic targets for traditional therapies is a hindrance to establishing a standardised therapy for TNBC. There is limited TNBCs epidemiological and real-world data about TNBC treatment regimens in Poland. We retrospectively analysed clinical data from our hospital registry from 2015 and 2020. A total of 8103 individuals with breast cancer were admitted to the MSCI, while 856 (10.6%) were diagnosed with TNBC. Most of the early-stage or locally advanced TNBC individuals had underlying conditions, presented mostly poorly differentiated (G3) stage II tumours and featured a bi-modal age distribution. On average, one-third of all tested TNBCs carried mutations and its identification impacted surgery preference. We observed a significant increase in the use of systemic therapy among TNBCs, whereas carboplatin and dose-dense regimens showed the most prominent upsurge in the neoadjuvant setting. Moreover, the use of neoadjuvants was positively correlated with less invasive breast and lymph node surgeries. The presented data align with general trends observed in other countries and will contribute to expanding knowledge in the planning of treatment regimens and their outcomes.
三阴性乳腺癌（TNBC）由于经常出现侵袭性、异质性和转移性肿瘤，带来了严峻的治疗挑战。传统疗法缺乏治疗靶点，这阻碍了为TNBC建立标准化治疗方案。波兰关于TNBC治疗方案的流行病学和真实世界数据有限。我们回顾性分析了我院2015年至2020年登记处的临床数据。共有8103例乳腺癌患者入住MSCI，其中856例（10.6%）被诊断为TNBC。大多数早期或局部晚期TNBC患者有基础疾病，主要表现为低分化（G3）II期肿瘤，且年龄分布呈双峰型。平均而言，所有检测的TNBC中有三分之一携带突变，其鉴定影响手术偏好。我们观察到TNBC患者中全身治疗的使用显著增加，而在新辅助治疗中，卡铂和剂量密集方案的使用激增最为显著。此外，新辅助治疗的使用与侵袭性较小的乳腺和淋巴结手术呈正相关。所呈现的数据与其他国家观察到的总体趋势一致，将有助于扩大治疗方案规划及其结果方面的知识。
